SGLT2 inhibition, circulating metabolites, and atrial fibrillation: a Mendelian randomization study.

ABSTRACT:

Background

Sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown promise in reducing the risk of atrial fibrillation (AF). However, the results are controversial and the underlying metabolic mechanism remains unclear. Emerging evidence implied that SGLT2 inhibitors have extra beneficial metabolic effects on circulating metabolites beyond glucose control, which might play a role in reducing the risk of AF. Hence, our study aimed to investigate the effect of circulating metabolites mediating SGLT2 inhibition in AF by Mendelian randomization (MR).

Methods

A two-sample and two-step MR study was conducted to evaluate the association of SGLT2 inhibition with AF and the mediation effects of circulating metabolites linking SGLT2 inhibition with AF. Genetic instruments for SGL

SUBMITTER: Li J 

PROVIDER: S-EPMC10583416 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature